BackgroundMelanoma is an aggressive cancer with complex etiology and poor prognosis. Surgical resection is still the primary treatment of melanoma, but shows limited efficacy in late-stage patients. Additionally, reliable prognostic markers of skin melanoma patients are still lacking. Circulating tumor cells (CTCs) have shown promise in predicting prognosis of multiple cancers.Evaluating the prognostic value of CTC number in melanoma patients.Material/MethodsCTCs were isolated by immunomagnetic capture from 7.5-mL samples of blood from 100 patients with cutaneous melanoma. Baseline CTC number (pre-treatment) and post-treatment CTC number were measured. Baseline CTC number and CTC number alteration were correlated with clinicopathological features and survival.ResultsForty-three (43%) patients had more than 6 CTCs, whereas 57 (57%) had 6 cells or less. High baseline CTC count was associated with deep local invasion, lymph node metastasis, and distance metastasis, with P value of 0.003, 0.047, and 0.034, respectively. High baseline CTC count was also correlated with short overall survival time and was considered as an independent prognostic factor (P value=0.012, hazard ratio=2.262). CTC cell alteration was associated with progression-free survival and disease-specific survival (with P values of 0.012 and 0.009, respectively).ConclusionsBaseline CTC count was correlated with adverse pathological features and was predictive of survival in melanoma patients. Alteration of CTC count before and after treatment was an indicator of therapy response and prognosis. Measuring the baseline and post-treatment CTC counts is a powerful tool in monitoring melanoma progression, drug response, and survival.
Post-acne keloids have become a serious problem affecting the physical and mental health of adolescents. However, traditional single-treatment methods have a high recurrence rate and are highly susceptible to a variety of complications. Postoperative radiotherapy has rapidly become a popular choice for comprehensive postoperative treatment because of its painlessness, non-invasiveness, convenience, low recurrence rate, and few complications. 1 In the available literature, no serious complications have been reported. Here we introduce a case of keloid after acne with isotope strontium-90 as a comprehensive treatment regimen, which leads to extensive depigmentation in the maxillofacial region. Combined with knowledge of the relevant literature, the mechanisms, types, and timing and dose, and reflect on balancing of recurrence rates and complications to deepen our understanding of the disease.
Skin mixed tumors are extremely rare clinically, lack characteristic manifestations, and are easily confused with other diseases. An Asian male came to our hospital's cosmetic and plastic surgery department because of a skin mass on the right side of his nose. After unanimous discussion by our doctors, the patient underwent subcutaneous tumor resection under local anesthesia and rotational flap transplantation to treat the disease and improve the shape of the nose. The surgery was a success. The patient was checked regularly, and the sutures were removed 1 week later. The patient's wound was normal after suture removal. During the 5-month follow-up, the patient's right nose showed no recurrence, the appearance was normal, and the scar was not obvious. The patient was satisfied.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.